Suchergebnisse - "Ofran, Yishai"

PubPharm (7)

1

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE) : part one of a randomised, phase 2, dose optimisation study

enthalten in: The Lancet. Haematology | 2023

von Pabst, T. | Papayannidis, C. | Demirkan, F. | +23

CommentIn: Lancet Haematol. 2023 Nov;10(11):e868-e870. - PMID 37914475

2

Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Azoulay, T. | Slouzky, I. | Karmona, M. | +5

3

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

enthalten in: American journal of hematology | 2021

von Apel, A. | Moshe, Y. | Ofran, Y. | +12

4

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

enthalten in: Scientific reports | 2020

von Hayun, M. | Zaatra, M. | Itzkovich, C. | +8

5

The role of specialized hospital units in infection and mortality risk reduction among patients with hematological cancers

enthalten in: PloS one | 2019

von Carmen, R. | Yom-Tov, G. | Van Nieuwenhuyse, I. | +2

6

Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death

enthalten in: Leukemia research | 2013

von Altman, J. | Rademaker, A. | Cull, E. | +22

CommentIn: Leuk Res. 2013 Oct;37(10):1391-2. - PMID 23906626

7

Treatment for relapsed acute myeloid leukemia : what is new?

enthalten in: Current opinion in hematology | 2012

von Ofran, Y. | Rowe, J.

1
[1]